

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to Commissioner of Patents and Trademarks, Washington, D.C. 20231 on May 15, 2002.

RECEIVED

Elise D. Bray

JUN 03 2002

TECH CENTER 1600/2900

Applicant : Wolfgang Wuttke, et al.
Application No. : 09/646,740
Filed : September 18, 2000
Title : UTILIZATION OF EXTRACTS FROM IRIS PLANTS, CIMICIFUGA
RACEMOSA AND TECTORIGENIN AS AN ESTROGEN-LIKE
ORGAN-SELECTIVE MEDICAMENT WITHOUT UTEROTROPIC
EFFECTS

Grp./Div. : 1651
Examiner : Michele C. Flood

Docket No. : 43687/KMO/W338

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Post Office Box 7068
Pasadena, CA 91109-7068
May 15, 2002

Commissioner:

In response to the Office action of November 15, 2001, please amend the above-identified application as follows:

In the Claims:

Please amend claims 17 and 18 and add new claim 26. All of pending claims 17 to 26 follow.

C1
17. (Amended) A method for producing an estrogen-type effect in a patient without causing a substantial uterotrophic effect, the method comprising administering to the patient an effective amount of a medicament comprising an extract from an Iridaceae plant, wherein the extract is selected from the group consisting of *Belamcanda chinensis*, *Iris Germanica*, *Iris tectorum*, *Iris Illyrica*, and *Iris dichotoma*,